Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thonzylamine is a first-generation ethylenediamine antihistamine and anticholinergic drug used primarily in combination with other agents for the temporary relief of symptoms associated with the common cold, hay fever (allergic rhinitis), or other upper respiratory allergies. It acts as an antagonist at the Histamine H1 receptor, thereby blocking the effects of histamine that lead to symptoms such as nasal congestion, runny nose, sneezing, and itching. Thonzylamine also exhibits anticholinergic properties. As a first-generation antihistamine, it readily crosses the blood-brain barrier and may cause sedation or central nervous system side effects. It is typically found in over-the-counter combination products with agents like phenylephrine or chlophedianol for symptomatic control of allergic rhinitis and related conditions[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thonzylamine.